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Kaposi sarcoma–associated herpesvirus infection is associated with the development of 3 proliferative diseases: Kaposi sarcoma,
primary effusion lymphoma, and multicentric Castleman disease. These conditions are also intimately associated with human
immunodeficiency virus infection, and important synergistic interactions between these 2 viruses have been described. Despite
differences in viral gene expression patterns in each condition, Kaposi sarcoma–associated herpesvirus encodes similar
oncogenic proteins that promote the activation of sequential and parallel signaling pathways. Therapeutic strategies have
been implemented to target these unique signaling pathways, and this sort of molecular targeting is the focus of many current
research efforts. The scope of this review is to present contemporary knowledge about the epidemiology, virology, and
immunology of Kaposi sarcoma–associated herpesvirus and to highlight several key oncogene products that may be targets
for chemotherapy.
In 1994, a previously unrecognized g-herpesvirus was discov-
ered by Chang and Moore [1] with use of representational
difference analysis to identify DNA fragments of this virus from
Kaposi sarcoma (KS) tissue samples. Named Kaposi sarcoma–
associated herpesvirus (KSHV), and also known as human her-
pesvirus-8, KSHV was subsequently identified in samples from
patients with primary effusion lymphoma (PEL) and multi-
centric Castleman disease (MCD) [2, 3]. This was more than
a coincidental finding; KSHV infection is a requisite for the
development of KS and PEL and is the pathogenic stimulant
for many cases of MCD, including all HIV-associated MCD.
In addition to these 3 “hallmark” diseases, other conditions,
such as hemophagocytic lymphohistiocytosis [4], have been
associated with KSHV.
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Although infection with KSHV is necessary for the devel-
opment of KSHV-associated disease, it is not sufficient. Both
HIV coinfection and immunosuppression significantly increase
the risk of KSHV-associated disease.
This review covers the basics of KSHV virology, epidemi-
ology, immunology as it relates to the immunosuppressed host,
and diagnosis. The key pathogenic mechanisms of KSHV that
lead to tumorigenesis will be highlighted, with an emphasis on
those mechanisms that use signaling pathways with known in-
hibitors. Additionally, the epidemiology, pathology, and clinical
and diagnostic features of the 3 classic KSHV-associated dis-
eases will be discussed. The rationale for antiviral therapy
against KSHV in each of these diseases is addressed.
KSHV EPIDEMIOLOGY
Information about the epidemiology of KS comes from cancer
registry data on the incidence of KS in various geographic and
demographic groups; serologic and molecular epidemiologic
studies have characterized the epidemiology of KSHV infection
[5–7]. KS was initially described as an uncommon tumor
among elderly Mediterranean men and was subsequently re-
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ported in African children in the 1960s [8, 9]. The association
with immunodeficiency was first reported in patients who were
undergoing solid-organ transplantation, but in 1981, an epi-
demic of KS among young men who have sex with men in the
United States served as the harbinger of a new immunodefi-
ciency syndrome, subsequently identified as being caused by
HIV [10, 11]. As the HIV epidemic progressed, KS was found
almost exclusively among men who have sex with men [12].
Coupled with epidemiologic data, which found KS to be more
common among persons who were at greater risk for sexually
transmitted infections, an infectious etiology of KS was sought.
After the identification of KSHV as the etiologic agent of
KS, the development of serologic assays allowed for seroepi-
demiologic studies that confirmed that KSHV prevalence varies
widely, from 1%–3% of blood donors in North America to
170% of individuals in regions of Africa where KSHV is en-
demic [13]. The seroprevalence of KSHV has been found to
roughly mirror the incidence of KS, although populations with
gross disparities between seroprevalence and incidence high-
light the importance of other potential cofactors in the pro-
gression from chronic KSHV infection to KS.
Definitive data on the mode of KSHV transmission are lack-
ing. There is evidence for sexual, horizontal, and parenteral
transmission in the medical literature. The virus is often shed
from the oropharynx of both immunocompetent and immu-
nocompromised men and women in areas where KSHV is en-
demic [14–16]. Behaviors associated with exposure to saliva are
correlated with a higher risk of KSHV infection, implicating
both sexual and horizontal transmission [17–19]. A relatively
high KSHV seroprevalence has been described among injection
drug users, and an increased incidence of KSHV infection has
been noted among transfusion recipients in areas where KSHV
is endemic, suggesting that parenteral transmission may be pos-
sible [20]. Finally, transmission of KSHV from donors of solid
organs has been described [21–23]. Taken together, these dis-
parate data make it difficult to counsel persons who are at risk
for KSHV-associated disease regarding methods to reduce their
risk of acquiring KSHV [24].
DIAGNOSIS AND VIROLOGY
An individual can receive a diagnosis of KSHV infection as a
result of receiving a diagnosis of KS or PEL. Many indirect
serologic tests for KSHV are available, although few commercial
assays exist. Serologic assays for KSHV infection are limited in
both sensitivity and specificity, and conflicting data have been
produced with different methodologies. Additionally, with the
limited availability of testing, there are few clinical indications
for KSHV serologic testing apart from epidemiologic or re-
search settings. Direct detection of KSHV DNA in clinical spec-
imens with use of PCR may be reasonable in a restricted set
of clinical conditions. Finally, in situ hybridization or immu-
nohistochemistry may reveal KSHV proteins expressed in hu-
man tissue, and these approaches are often used adjunctively
in the diagnosis of KS, PEL, or MCD.
Like all herpesviruses, KSHV alternates between 2 phases of
its life cycle. The lytic phase is hallmarked by active viral rep-
lication, and a wide range of KSHV gene products are expressed
during this phase [25]. During the latent phase, however, gene
expression is extremely limited. The virus is maintained as ep-
isomes attached to the host chromosome, is replicated with the
host chromosomes, and is subsequently passed to daughter
cells. KSHV-associated diseases vary in the degree of replication
during the lytic phase. During the lytic phase, KS lesions are
associated with limited viral replication, MCD is associated with
a very high degree of viral replication, and PEL is associated
with an intermediate level of viral replication.
PATHOGENESIS OF KSHV-ASSOCIATED
TUMORIGENESIS
KSHV encodes for numerous specific proteins that are pos-
tulated to play a role in the pathogenesis of KS, PEL, and MCD.
Many of these proteins have been pirated from the human host
during the course of viral evolution. KSHV produces molecules
that are critical in the transduction of signals that stimulate cell
proliferation and inhibit apoptosis. The latency-associated nu-
clear antigen is one such protein that primarily functions to
tether the viral genome to the infected host-cell’s genome; how-
ever, it also promotes cell survival and contributes to the trans-
formation of KSHV-infected cells by interacting with and al-
tering the function of the tumor suppressor proteins p53 and
retinoblastoma protein [26–28]. Another example is the viral
G protein–coupled receptor, a lytic-phase gene product that
shares significant homology with the high-affinity IL-8 receptor.
Its dysregulated expression leads to oncogenesis through nu-
merous cellular proliferation, transformation, proangiogenic,
and antiapoptotic signaling pathways [29, 30]. The viral G pro-
tein–coupled receptor leads to proangiogenic signals by the
upregulation of hypoxia-inducible factor 1-a and the subse-
quent expression of vascular endothelial growth factor (VEGF)–
A and activation of VEGF-receptor-2, which in turn activates
the phosphatidyl-inositol-3–kinase, Akt, and mammalian target
of rapamycin (mTOR) pathway [29]. Additionally, blockade of
the viral G protein–coupled receptor and inhibition of pho-
phatidyl-inositol-3–kinase leads to inactivation of the tran-
scription factor and antiapoptotic protein nuclear factor–kB
(NF-kB), thereby blocking transformation [29]. A third on-
cogenic protein is the viral FLICE inhibitory protein, which is
associated with constitutively activated NF-kB and is purported
to function as an oncogene through the manipulation of this
pathway [31, 32]. Lastly, KSHV encodes for a human IL-6
homologue, viral IL-6, which stimulates the known human IL-
6–induced signaling pathways via the shared cytokine signaling
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Figure 1. Extensive papular-nodular Kaposi sarcoma on the leg (A) and back (B) of a patient from Uganda. C, Cutaneous Kaposi sarcoma of plaque
stage (hematoxylin-eosin stain; original magnification, 200). D, Kaposi sarcoma cutaneous tumor in which the spindled tumor cells demonstrate
Kaposi sarcoma–associated herpesvirus immunoreactivity (latency-associated nuclear antigen immunohistochemical stain; original magnification, 200).
receptor gp130 coupled to the endogenous JAK-STAT pathway
[33]. KSHV-infected cells induce and secrete viral IL-6 and can
retain some portion of viral IL-6 intracellularly, which then
binds to gp130 and activates STAT3 in an autocrine fashion
[29].
Inhibitors to many of the mentioned pathways exist, are
approved by the US Food and Drug Administration (FDA) for
other indications, and may offer substantial therapeutic benefit
in the treatment of KSHV-associated diseases. Anti-VEGF
agents include bevacizumab, sunitinib, and sorafenib; inhibitors
of mTOR include rapamycin, temsirolimus, and everlimus; and
the proteosome inhibitor bortezomib blocks the effects of NF-
kB. Inhibitors of the JAK and STAT pathways are being inves-
tigated for the treatment of various diseases, but none are FDA-
approved for any indication at this time. Additionally,
antibodies to IL-6 may be effective in treating some patients
with MCD [34].
KSHV IN THE IMMUNOCOMPROMISED HOST
Clinical observations identify T cells as playing an important
role in the control of KS, evidenced by the regression of KS
with the reduction of immunosuppressive treatment after trans-
plant and by clinical improvement and possible exacerbation
(flare) of KS in subjects with immune reconstitution after re-
ceipt of HAART [35, 36]. Studies have found that HIV-infected
KSHV-seropositive men do not have T cell proliferative re-
sponses to KSHV and that HIV-positive and HIV-negative per-
sons with KS have low quantities of KSHV-specific T cells [37,
38]. In addition, increased cytotoxic lymphocyte responses to
KSHV in HIV-infected persons who are receiving HAART have
been shown, although the recent reporting of persistent KS
despite effective HAART raises important questions about the
mechanisms that control the progression of KSHV infection
and KS [39, 40].
In experimental models, a relationship exists between KSHV
and HIV in which the replication of each virus may be enhanced
in the presence of the other. HIV Tat, for example, upregulates
HIV gene expression and has been shown to play a crucial role
in the development of KS via interaction with KSHV gene
products. Tat promotes the migration and proliferation of cy-
tokine-activated endothelial cells and stimulates KS cell growth
in mouse models [41]. Accordingly, when injected subcuta-
neously into nude mice, Tat causes KS-like lesions [42]. More-
over, ∼15% of male transgenic mice overexpressing the tat gene
develop skin tumors resembling KS at 12–18 months of age
[42].
Similarly, KSHV infection may enhance HIV replication [43].
The latency-associated nuclear antigen has been shown to ac-
tivate long terminal repeats of HIV-1 through its association
with Tat [44]. Interestingly, HIV infection leads to increased
KSHV infectivity because of Tat [45]. It is believed that the
actions of Tat may account for the rather aggressive course of
KS in patients with AIDS, compared with the more indolent
behavior of KS in HIV-negative persons.
KSHV-ASSOCIATED DISEASES: CLINICAL
PRESENTATION AND MANAGEMENT
KS. KS occurs in several clinical-epidemiologic settings [46].
Classic KS is a nonaggressive disease that usually affects elderly
Mediterranean men, is not associated with HIV infection, and
presents with a limited number of cutaneous lesions on the
lower extremities; disseminated disease is uncommon. Endemic
KS affects persons from sub-Saharan Africa and is also not
associated with HIV. Endemic KS is a more aggressive and
morbid disease than classic KS (figure 1). Immunodeficiency
clearly enables KS development, and patients who are taking
immunomodulatory agents—most notably in the context of
solid-organ transplantation—often develop transplant-associ-
ated KS. Lastly, AIDS-associated or “epidemic” KS is the most
common cause of tumor development among HIV-infected
patients. It is often characterized by widely disseminated cu-
taneous disease, with advanced cases involving the oral mucosa
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and viscera (most frequently the lungs and gastrointestinal
tract).
A wide range of treatments for KS are available. Independent
of any other clinical factor, all patients with AIDS-associated
KS should receive HAART [46]. Effective antiretroviral regi-
mens are associated with a reduction in the incidence of AIDS-
related KS, a regression in the size and number of existing
lesions, and a histological regression of existing KS lesions. Few
data exist on the comparative efficacy of various HAART reg-
imens in the treatment of KS, although experimental models
and anecdotal data may support the sole use of protease in-
hibitor–containing regimens [47]. Several antiviral agents, in-
cluding ganciclovir, foscarnet, and cidofovir, have been shown
to inhibit KSHV replication in vitro. Antiviral therapy (with
cidofovir) aimed at KSHV has not been shown to be effective
by itself for the treatment of KS, perhaps in part because of
the small amount of lytic KSHV that is present in KS tumors
[48, 49]. Antiviral treatments may be effective as an adjunct to
more-conventional chemotherapy or in the treatment of dis-
eases with a higher degree of lytic replication (i.e., MCD and
PEL).
The clinical context of KS (i.e., HIV status, transplant status,
and extent and site of disease) is crucial for the selection of
appropriate treatment. Patients with limited local disease may
benefit from a variety of therapies, including intralesional che-
motherapy (vinblastine is most commonly used), topical oint-
ments (alitretinoin gel), cryotherapy, laser therapy, photody-
namic therapy, and infrequently, excisional surgery. Radiation
therapy can effectively palliate symptomatic disease that is not
extensive enough to warrant systemic therapy but is too ex-
tensive to be treated with intralesional chemotherapy. Patients
with rapidly progressing, extensive cutaneous and/or visceral
disease should receive systemic therapy. Systemic treatments
have traditionally involved cytotoxic chemotherapy. Although
numerous chemotherapeutic agents have been shown to be
effective, only 3 have been approved by the FDA for this in-
dication on the basis of clinical effectiveness and a reasonable
adverse-effects profile. They include the 2 liposomal anthra-
cyclines (pegylated liposomal doxorubicin and liposomal dau-
norubicin) and the taxane paclitaxel. Nontraditional therapies
have been the focus of recent clinical investigation in the field.
Some nontraditional therapies have shown promise in early
clinical trials (thalidomide, imatinib, and COL3), and some are
actively being investigated in clinical trials (rapamycin, beva-
cizumab, sunitinib, and sorafenib) [46].
Lastly, patients who develop KS while receiving immunom-
odulatory agents should, when feasible, receive an immuno-
suppressive regimen that includes rapamycin or one of its an-
alogues. This recommendation is based on a series of
solid-organ transplant recipients in whom KS regressed after
treatment was switched to rapamycin [50].
PEL. PEL is an unusual lymphoproliferative disorder, ac-
counting for 2% of HIV-associated lymphomas, and is even
more rarely encountered in the HIV-negative population. PEL
is divided into classic and solid variants. Classic PEL is char-
acterized by lymphomatous involvement of the serosal surfaces,
whereas solid PEL manifests initially with tissue-based tumors
and no malignant effusions (figure 2) [ 51, 52]. Classic and
solid PEL are similar with regard to morphology, immuno-
phenotype, and molecular characteristics [53]. KSHV and high
levels of interleukin (e.g., IL-6) may be found in PEL tumor
cells, and this has frequently been demonstrated to aid in di-
agnosis. The ramifications of large and typically recurrent pleu-
ral, pericardial, and peritoneal effusions are grave and are re-
sponsible for the high morbidity and mortality associated with
this condition [52].
PEL cells have a characteristic phenotype highlighted by
CD45, CD30, CD38, CD138, and MUM1 coexpression [52].
Classic B cell markers (CD19 and CD20) and T cell markers
(CD2, CD3, CD5, and CD7) are not typically seen. Gene ex-
pression profiling has shown that PEL expresses a gene profile
distinct from other lymphomas but more akin to multiple my-
eloma cell lines.
There is no clear standard of care established in the treatment
of PEL, and because of its low incidence, randomized clinical
trials are not feasible. As with the other KSHV-associated dis-
eases, if HIV coinfection is identified, antiretroviral therapy is
critical, because spontaneous regression with the commence-
ment of HAART has been described [52, 54]. Traditionally, the
use of standard cytotoxic regimens used for the treatment of
non-Hodgkin lymphomas are suboptimal, and median dura-
tion of survival in treated cohorts is poor [55]. Induction of
apoptosis with the inhibition of NF-kB in PEL cell lines has
led to the investigation of proteasome inhibitors that decrease
the activation of NF-kB and its antiapoptotic effects [56]. Bor-
tezomib, a proteosome inhibitor that has been approved by the
FDA for use in multiple myeloma, has been shown to enhance
the in vitro cytotoxic effects of doxorubicin and paclitaxel, and
has been used successfully in combination with anthracycline-
based cytotoxic chemotherapy regimens [57]. Inhibition of
mTOR with rapamycin is effective at decreasing in vitro PEL
growth and in vivo mouse xenograft model tumor growth, and
its increasing use in the treatment of PEL can be foreseen [58].
Cases of prolonged survival for patients who were treated ad-
junctively with antiviral therapy (ganciclovir or cidofovir) have
also prompted the adjunctive use of these drugs in PEL. When
used to treat PEL, valproate induces lytic KSHV replication and
leads to apoptosis in combination with antiviral agents [47].
MCD. MCD is an aggressive lymphoproliferative disorder
that is characterized by constitutional symptoms, anemia, and
generalized lymphadenopathy (figure 3). Small case-series have
shown that most MCD cases are driven by KSHV, including
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Figure 2. A, Pericardial primary effusion lymphoma (CT of the chest).
B, Photomicrograph of pericardial fluid, cytospin preparation with atypical
lymphoid cells with basophilic cytoplasm and vacuolization (Wright-
Giemsa stain; original magnification, 600); inset, prominent mitosis
(arrow) in one of the lymphoma cells. C, HIV-associated primary effusion
lymphoma showing lymphoma cells with Kaposi sarcoma–associated her-
pesvirus viral nuclear inclusions (cell block preparation; hematoxylin-eosin
stain; original magnification, 600). Images in figure 2A and 2B originally
appeared in Braza et al. [51] and were reprinted with permission from
CMPMedica.
Figure 3. Lymph node with HIV-associated multicentric Castleman dis-
ease showing multiple regressing follicles surrounded by an expanded
and vascular interfollicular zone (hematoxylin-eosin stain; original mag-
nification, 100).
100% of cases among HIV-positive patients and the majority
of cases among HIV-negative patients [59]. Failure to identify
KSHV in all MCD lesions may reflect technical limitations in
KSHV detection, the ability of KSHV to induce MCD from a
distance in the biopsied tissue, or an alternate etiology for a
limited number of cases. On occasion, MCD may be associated
with non-Hodgkin lymphoma, particularly the plasmablastic
variant [33]. A key to making a diagnosis of MCD is to suspect
MCD in high-risk individuals who present in the appropriate
clinical context (i.e., an immunosuppressed individual with
KSHV infection or other KSHV-associated disease). Definitive
diagnosis can only be made by pathologic examination of an
involved lymph node or extranodal mass. Detection of KSHV
in biopsied tissue or in the peripheral blood can aid in the
diagnosis. C-reactive protein, KSHV load, and serum IL-6 lev-
els, if available, may be useful as markers of disease activity
and response to therapy [33].
In patients with MCD and HIV infection, treatment with
antiretroviral therapy is necessary, but caution should be taken,
because life-threatening flares of MCD have been reported as
a manifestation of immune reconstitution [60]. Systemic ther-
apy is the mainstay of treatment for patients with MCD and
includes aggressive remission-induction chemotherapy regi-
mens (cyclophosphamide-doxorubicin-vincristine-prednisone
or doxorubicin-bleomycin-vincristine), single-agent mainte-
nance chemotherapy (oral etoposide, cyclophosphamide, or
vinblastine), immunomodulatory agents (thalidomide or IFN-
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a), and monoclonal antibodies against the IL-6 receptor (al-
tizumab) and CD20 (rituximab) [33].
Among all of these treatments, rituximab has shown the most
promise in inducing durable remission of MCD. In a pro-
spective study of 24 individuals with chemotherapy-dependent
HIV-associated MCD, rituximab was associated with sustained
remission at day 60 after treatment (the primary end point) in
22 patients (92%) [61]. More recently, the efficacy and safety
of 4 weekly infusions of rituximab in 21 consecutive patients
with previously untreated plasmablastic HIV-associated MCD
has been investigated [62]. All but 1 patient achieved clinical
remission of symptoms, as well as hematological and serum
chemistry normalization, and 70% of patients achieved a ra-
diological response. In 3 patients who experienced relapse, re-
treatment with rituximab was successful [63]. The main adverse
event seen in these patients was reactivation of KS, which is
intriguing and may be attributable to a rapid B cell depletion
that is observed during rituximab therapy or to an immune
reconstitution inflammatory syndrome to hitherto latent an-
tigens [64]. Rituximab therapy was shown to be associated with
a decrease in KSHV levels both initially and at the successful
treatment of a relapse [62].
Because of the lytic nature of KSHV in MCD, antiviral ther-
apy is also a consideration. A recent randomized, controlled
trial demonstrated the efficacy of valganciclovir in reducing
KSHV replication in individuals with KSHV infection but with-
out evidence of KS, PEL, or MCD [65]. In patients with MCD,
ganciclovir and valganciclovir have been independently shown
to induce remissions alone or in combination with other agents
[66, 67].
CONCLUSIONS
Differential KSHV gene expression has the ability to promote
the development of 3 distinct neoplastic conditions—KS, PEL,
and MCD. Emerging knowledge about the various signal trans-
duction pathways used by KSHV to mediate oncogenesis has
helped to identify numerous drug targets. Promising thera-
peutic targets include mTOR and VEGF for KS; mTOR, NF-
kB, and VEGF for PEL; and CD20+ B cells and KSHV-lytic
replication for MCD. Additionally, continued basic research
focusing on KSHV gene products and their functions may un-
cover more telling details about the upregulation and utilization
of molecular pathways that should provide additional and
more-efficient therapeutic targets.
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